MedTrace Logo

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

NCT06898957 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-05-20

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

Conditions

Interventions

DRUG

YL201

YL201 will be administered as an IV infusion.

DRUG

Tarlatamab

Tarlatamab will be administered as an IV infusion.

DRUG

Durvalumab

Durvalumab will be administered as an IV infusion.

Sponsors & Collaborators

  • MediLink

    collaborator UNKNOWN

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-16
Primary Completion
2031-06-23
Completion
2031-06-23
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06898957 on ClinicalTrials.gov